MCK

AlphaInsight Score 83/100

McKesson Corporation · Health Care

83
AlphaInsight Score
Momentum82
Valuation75
Growth78
Safety89

McKesson Corporation distributes pharmaceuticals, medical-surgical supplies, and oncology practice management solutions worldwide. The stock is driven by resilient GLP-1 distribution volume gains and higher-margin specialty oncology network expansion via US Oncology Network.

Market cap
$77B
P/E ratio
24.3
EPS growth
14.2%
Revenue growth
11.5%
Dividend yield
0.5%
Beta (5Y)
0.54
RSI (14)
56

The AlphaInsight Score is a proprietary 0–100 composite of momentum, valuation, growth and safety factors. Research snapshot updated 2026-09-05.

Bull case

Consistent secular growth in high-cost specialty therapeutics and GLP-1 medications drives robust distribution revenue throughput. Steady growth in the US Oncology Network and biopharma technology services diversifies revenue toward higher-margin streams. Disciplined capital deployment via steady share repurchases and dividend increases consistently compound earnings per share.

Bear case

Extremely low operating margins characteristic of wholesale distribution leave little room for error if supply contracts undergo repricing. Government and regulatory efforts to overhaul pharmaceutical drug supply chains could compress distribution fees. Loss of major retail pharmacy chain supply contracts could cause headline revenue contractions.

MCK FAQ

What is the AlphaInsight Score for MCK?

McKesson Corporation scores 83/100 on the AlphaInsight Score — ranked #42 of 656 stocks in our research universe. It blends momentum (82/100), valuation (75/100), growth (78/100) and safety (89/100).

Is MCK a buy right now?

MCK currently carries an AlphaInsight Score of 83/100 in our research system. Subscribers receive daily entry, target and stop-loss levels whenever it appears in a slate.

What are the biggest risks with MCK?

Extremely low operating margins characteristic of wholesale distribution leave little room for error if supply contracts undergo repricing. Government and regulatory efforts to overhaul pharmaceutical drug supply chains could compress distribution fees. Loss of major retail pharmacy chain supply contracts could cause headline revenue contractions.

How does MCK compare to its peers?

Compare MCK head-to-head with COR, CI, CVS on AlphaInsight Scores, valuation, growth and safety factors.

Get the full research on MCK

Subscribers get the complete thesis, risk factors and technical breakdown for MCKand 10 researched ideas every trading day.

Cancel anytime · Secure checkout

Cite & share this research

Ready-to-paste citation snippets for forums, Reddit, X or your own site.

Markdown (Reddit, X, forums)
[MCK stock research — AlphaInsight Score & technical signals](https://alphainsightai.net/stocks/MCK)
HTML (websites, blogs)
<a href="https://alphainsightai.net/stocks/MCK">MCK stock research — AlphaInsight Score & technical signals</a>
Alpha Insight AI provides AI-generated analysis for informational purposes only and is not investment advice. All investing involves risk, including the possible loss of principal.